Stocktoria
Editas Medicine, Inc. EDIT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2016-02-03
Editas Medicine, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Net margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% |
| FCF margin | -409.3% | -678.1% | -175.2% | -920.6% | -672.5% |
| Return on assets | -85.8% | -69.4% | -30.7% | -42.9% | -28.4% |
| Return on equity | -586.6% | -176.6% | -43.9% | -61.1% | -34.8% |
| Debt / equity | 1.96× | 0.43× | 0.00× | — | — |
| Current ratio | 3.54 | 3.75 | 5.39 | 5.94 | 10.82 |
| Revenue growth | 25.4% | -58.6% | 296.3% | -22.8% | -71.8% |
Source: SEC EDGAR filings · CIK 0001650664 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.